57 filings
8-K
GRI
GRI Bio Inc
22 May 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:45pm
8-K
GRI
GRI Bio Inc
20 May 24
Entry into a Material Definitive Agreement
4:13pm
8-K
GRI
GRI Bio Inc
13 May 24
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
8:02am
8-K
GRI
GRI Bio Inc
1 Apr 24
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
9:13am
8-K
GRI
GRI Bio Inc
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
8-K
xx5q 2gcczv
30 Jan 24
GRI Bio Announces Reverse Stock Split
8:12am
8-K
p9xjgn5hasiprmto4pql
19 Jan 24
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
5ucp8
16 Jan 24
Regulation FD Disclosure
8:45am
8-K
oen17b
5 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:05pm
8-K
ouc0b3qksa
5 Dec 23
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway
9:07am
8-K
6lmy2
27 Nov 23
Clinical development plan leveraging 505(b)(2) regulatory pathway
8:38am
8-K
qwkxf3kuxt8w38dt2ipr
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
8-K
qjftrq 14z5fm4a
15 Nov 23
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024
8:07am
8-K
eyz125
1 Nov 23
Regulation FD Disclosure
8:45am
8-K
11qjxm tu
25 Aug 23
Regulation FD Disclosure
4:42pm
8-K
q0xiiejaf7c3he5w3
23 Aug 23
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
9:07am
8-K
aeryy5q6
14 Aug 23
On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023
8:06am
8-K
mezqkjp
7 Jul 23
Submission of Matters to a Vote of Security Holders
4:03pm
8-K/A
rvia bh8mzn
6 Jul 23
Financial Statements and Exhibits
4:28pm
8-K/A
4js2z7at99wj8857moj
26 May 23
Financial Statements and Exhibits
4:15pm